FTO/m6A/GPNMB axis: a novel promising target for hepatocellular carcinoma (HCC) treatment?

2024/08/01 by Bernd Heinrich, Francisco Javier Cubero · 4 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #RNA modifications and cancer #Cardiac Structural Anomalies and Repair #Peptidase Inhibition and Analysis

paper · doi:10.1136/gutjnl-2024-332934

Cited by

• Glycoprotein nonmetastatic B as a pharmacological target in cancer: structural mechanisms, druggability, and therapeutic translation
• New insights into N6-methyladenosine in hepatocellular carcinoma immunotherapy. [europepmc]
• FTO Promotes Hepatocellular Carcinoma Progression by Mediating m6A Modification of BUB1 and Targeting TGF-βR1 to Activate the TGF-β Signaling Pathway. [europepmc]
• Hypoxia-induced m 6 A demethylation promotes hepatocellular carcinoma progression by preventing the degradation of Gal-1 mRNA. [europepmc]